Researchers from Aarhus University in Denmark published research indicating that Parkinson’s disease is actually two types of the disease.
Novartis’ Beovu matched Regeneron’s Eylea in vision clarity scores for a blindness-causing eye disease, the Swiss drugmaker said, after early safety stumbles for the medicine in another condition caused disappointing early sales.
The U.S. Food and Drug Administration issued a Complete Response Letter, a rejection, of Allergan’s Biologics License Application for Abicipar pegol for neovascular age-related macular degeneration.
Molecular Partners aims to test a COVID-19 drug candidate on people during 2020, Chief Executive Patrick Amstutz said, as the Swiss company hopes that project will help it recover from the failure of the eye drug abicipar.
Swiss drugmakers Roche and Novartis underscored how their portfolios are increasingly clashing on the commercial battlefield, announcing new data on drugs aimed at capturing market share from each other.
Recent personnel updates within the healthcare industry include Foundation Medicine veteran Thomas Civik being named president and chief executive officer of Five Prime Therapeutics.
Johnson & Johnson Vision announced the launch of Prioritize Your Eyes, a worldwide effort to raise awareness about the connection of eye health to overall health.
KalVista Pharmaceuticals indicated that Merck had allowed the option deal between the companies for the intravitreal diabetic macular edema (IDME) drug KVD001 and future DME molecules to expire.
Microsoft announced AI for Health, a new $40 million program which is part of the AI for Good initiative that will leverage artificial intelligence technology to “empower researchers and organizations addressing some of the world’s toughest challenges in health.”
Takeda Pharmaceutical Co. trimmed the company’s full-year fiscal 2019 loss forecast on strong sales of core drugs and progress in consolidating with Shire Plc.
